share_log

Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral, Raises Price Target to $32

Goldman Sachs Upgrades Agios Pharmaceuticals to Neutral, Raises Price Target to $32

高盛将Agios PharmPharmticals评级上调至中性,将目标价上调至32美元
Benzinga Real-time News ·  2022/11/17 08:26

Goldman Sachs analyst Salveen Richter upgrades Agios Pharmaceuticals (NASDAQ:AGIO) from Sell to Neutral and raises the price target from $17 to $32.

高盛分析师Salveen Richter将Agios PharmPharmticals(纳斯达克:AGIO)评级从卖出上调至中性,并将目标价从17美元上调至32美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发